ScholarWorks@Korea University College of Medicine: Choi, Yoon Ji

Detailed Information

Choi, Yoon Ji(최윤지)

안암병원 (Department of Medical Oncology and Hematology, Anam Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:5||Breast cancer:4||Breast neoplasms:3||Chemotherapy:3||PDL1:2||prognosis:2||prognostic model:2||Colorectal neoplasms:2||Highthroughput nucleotide sequencing:2||cellfree DNA:2||Korea National Health and Nutrition Examination Survey:2||Febrile neutropenia:2||Genomics:2||overall survival:2||Cancer survivors:1||Carboplatin:1||Cardiac Tamponade:1||Castrationresistant prostate cancer:1||Castrationresistant prostatic neoplasm:1||Cellfree nucleic acids quantification:1||Cessation:1||Cisplatin:1||Cisplatinunfit:1||Clostridium difficile:1||Comorbidity:1||Congestive heart failure:1||Continuity of patient care:1||Doubleballoon enteroscopy:1||Dovitinib:1||Ecigarettes:1||Endoflife care:1||Enfortumab vedotin:1||Epidermal growth factor receptor mutation:1||Eribulin:1||FOLFIRI:1||FOLFOX:1||Gefitinib:1||Gemcitabine:1||Goserelin:1||Hereditary nonpolyposis colon cancer:1||Hyponatremia:1||IFNγ:1||Inflammation:1||Intercalated chemotherapy:1||Jejunal neoplasm:1||KRAS:1||Khorana score:1||Korean:1||Liver:1||Lung adenocarcinoma:1||Lymph node excision:1||Lymph nodes:1||Lymphoma:1||Malignancy:1||Metabolic tumor volume:1||Metastasis:1||Metastatic burden:1||Metastatic cancer:1||Molecular:1||Mutation:1||Neoadjuvant therapy:1||Neoplasm:1||Neoplasm metastasis:1||Neoplasms:1||Neuroendocrine carcinoma (NEC):1||Neuroendocrine tumor (NET):1||Neutropenia:1||Nonsmall cell lung cancer:1||Nonsmallcell lung cancer:1||Nonsmallcell lung carcinoma:1||Octreotide:1||Ovarian function suppression:1||Ovarian neoplasms:1||Overall survival:1||Oxaliplatin:1||PDL2:1||PIK3CA mutation:1||Pancreatic adenocarcinoma:1||Pancreatic cancer:1||Pancreatic neoplasms:1||Pathology:1||Pemetrexed:1||Phase IV clinical trial:1||Physician orders for lifesustaining treatment:1||Pneumonitis:1||Postprogression survival:1||Practice guideline:1||Precision medicine:1||Predictive value:1||Prednisolone:1||Premenopause:1||Primary Pericardial Mesothelioma:1||Principal component analysis:1||Prognostic biomarker:1||Prognostic factors:1||Prostate neoplasms:1||Safety:1||Secondline chemotherapy:1||Serum:1||Small cell lung cancer:1||Smoker:1||Smoking:1||Stage:1||Survival:1||TGFβ1:1||TNFα:1||Tamoxifen:1||Targetable gene alteration:1||Total lesion glycolysis:1||Toxocariasis:1||Trastuzumab:1||Treatment outcome:1||Tyrosine kinase inhibitors:1||Urinary bladder:1||Urothelial cancer:1||Urothelial carcinoma:1||Venous thromboembolism:1||Visceral larva migrans:1||WildType EGFR:1||aggressive fibromatosis:1||bladder cancer:1||brain metastasis:1||cancer:1||cancer patients:1||cancer survivors:1||capecitabine:1||cardiovascular disease:1||cellfree DNA concentration:1||chemotherapy:1||cholangiocarcinoma:1||cisplatin:1||colorectal cancer:1||coronavirus disease 2019:1||direct oral anticoagulants:1||hand strength:1||head and neck cancer:1||leucovorin:1||lowmolecularweight heparin:1||lung cancer:1||lung function:1||malignant salivary gland tumors:1||mammalian target of rapamycin inhibitor (mTOR inhibitor):1||methotrexate:1||missense mutation:1||mitomycin:1||molecular targeted therapy:1||multiplex polymerase chain reaction:1||mutations:1||neoplasms:1||nonsmall cell lung cancer:1||nonsmallcell lung cancer:1||nonsmallcell lung carcinoma:1||obstructive lung disease:1||pemetrexed:1||perception:1||prognostic indicator:1||prognostic value:1||quality of life:1||refractory colon cancer:1||relapsefree survival:1||risk:1||safety:1||screening:1||secondline chemotherapy:1||sequencing:1||sirolimus:1||stroke:1||survivorship:1||tumorinfiltrating lymphocytes:1||urothelial carcinoma:1||vaccine:1||venous thromboembolism:1||5FU:1||vinblastine:1||Adjuvant chemotherapy:1||Adjuvant endocrine therapy:1||Advance directives:1||Advanced lung cancer:1||Anthracycline:1||BRCA1 gene:1||Biliary tract cancer:1||Biomarkers:1||Bone morphogenetic protein2:1||COVID19:1||CTLA4:1||CXCR4:1||Cabazitaxel:1||

STATISTICS: Total View :7,654,597; Today View :8,360

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841) 82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE